All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

refresh

Product Type

Companies

89bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial

Contact the Supplier

Lead Product(s): BIO89-100

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 13, 2020

Details:

The company closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic.

Dicerna Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

BIO International Convention

Participation Not Confirmed

Update your events

Dicerna Receives Orphan Drug Designation From FDA for DCR-A1AT

Contact the Supplier

Lead Product(s): DCR-A1AT

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2020

Details:

The Company expects to dose the first patient in the second half of 2020.